Issues relating to drug pricing policy. Pharmacy benefit manager legislation related to patient access to therapies. H.R. 1492/S. 832, EPIC Act. H.R. 1672, MINI Act.
Literal federal measure citations: H.R. 1492, S. 832, H.R. 1672
Source-reported fields
Filing overview
- Type
- 2nd Quarter - Report
- Posted
- Jul 18, 2025
- Income
- $40,000.00
- Expenses
- Not reported
- Registrant
- DLA PIPER LLP (US)
- Client
- NOVARTIS
- Filing UUID
- 444f7fea-eeff-45b0-811d-17fcedd3d592
- Termination date
- Not reported
Literal source text
Lobbying issues and bill citations
Issues related to rare disease and treatment. Drug and pricing policy. Issues related to the Medicaid 340B program. Public policy around patients' access and affordability. Issues related to Medicare Part B and D.
Intellectual property protections and enforcement. Biopharmaceutical patent policy.
Tax reform and tax policy.
Tariffs.
Relationship and amount limits
Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.